`

Tagged: Biomarker development

Interest is increasing rapidly in using surrogate markers as primary measures of the effectiveness of investigational drugs in definitive drug trials.

January 10th, 2023 | Biomarker development

The primary difference between a biomarker and a surrogate marker is that a biomarker is a “candidate” surrogate marker. In contrast, a surrogate marker is a test used and taken to measure the effects of a specific treatment. While the current law and regulations permit the FDA to base the approval of a drug product […]

With Biomarkers now a routine part of drug development, BBCR assists companies with the identification and adoption of biomarkers, especially valuable in rare disease and precision medicine product development.

September 22nd, 2021 | Biomarker development

The FDA recognizes biomarker development as a high priority area for future research. BBCR can help your company with your product development plan and validation.  

Pin It on Pinterest